LabGenomics Supplies Oral Microbiome Test 'BioRalCare'... "Expecting Business Expansion"

LabGenomics announced on the 18th that it has signed a BiOralCare TM service contract with BS Dental Hospital located in Incheon.

The company is aggressively expanding its microbiome testing business. Since entering an online specialty mall targeting hospitals operated by major domestic pharmaceutical companies in August, it has continued to secure supply contracts with profitable dental hospitals.

Oral microbiome testing identifies metabolic diseases such as body mass index, obesity, and diabetes through simple and easy oral examinations. In addition, it can test for a total of 26 various diseases, including mental disorders such as Alzheimer's, insomnia, depression, as well as inflammatory and cancer diseases. Based on the test results, it provides solutions and guidelines to predict and reduce the risk of diseases.

The company explained that periodic microbiome testing creates a virtuous cycle for the company, hospitals, and patients. Patients can regularly track and manage their oral health status, while dental hospitals can increase patient visit frequency, enabling the establishment of a sustainable revenue model. Through this, the company can generate continuous sales, expand its business areas, and build new business models.

A LabGenomics representative stated, “It is expected that more than 300 to 500 tests will be conducted monthly at each dental hospital,” adding, “This will greatly help hospitals attract patients by allowing them to suggest tests to patients regularly.”

He further emphasized, “In the future, we expect to expand oral microbiome testing mainly to dental hospitals nationwide and broaden the supply scope to related markets such as diet and chronic disease using metabolic disease testing.”

Meanwhile, the oral microbiome test developed and supplied directly by LabGenomics collects oral microorganisms using a swab-type kit. The collected microorganisms are analyzed using the 16S Ribosomal RNA gene analysis method based on NGS (Next-Generation Sequencing) to distinguish harmful bacteria from beneficial bacteria.

This content was produced with the assistance of AI translation services.